Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaojun Zhu

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Plos Medicine|January 25, 2008
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaTim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
JAMA Oncology|September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging TrialThomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
Cell Metabolism|May 28, 2013
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancerIvan Babic, Erik S Anderson, Kazuhiro Tanaka, et al.
Science (New York, N.Y.)|December 7, 2013
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNADavid A Nathanson, Beatrice Gini, Jack Mottahedeh, et al.
The New England Journal of Medicine|November 12, 2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitorsIngo K Mellinghoff, Maria Y Wang, Igor Vivanco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Cancer Research|August 20, 2009
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patientsKan V Lu, Shaojun Zhu, Anna Cvrljevic, et al.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Plos Medicine|January 25, 2008
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaTim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
JAMA Oncology|September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging TrialThomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
Cell Metabolism|May 28, 2013
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancerIvan Babic, Erik S Anderson, Kazuhiro Tanaka, et al.
Science (New York, N.Y.)|December 7, 2013
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNADavid A Nathanson, Beatrice Gini, Jack Mottahedeh, et al.
The New England Journal of Medicine|November 12, 2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitorsIngo K Mellinghoff, Maria Y Wang, Igor Vivanco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Cancer Research|August 20, 2009
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patientsKan V Lu, Shaojun Zhu, Anna Cvrljevic, et al.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
Pageof 9